"ODYSSEY Outcomes: Alirocumab Lowers CV Events In ACS Population" - Erik Swain
Reducing LDL to very low levels with the PCSK9 inhibitor alirocumab lowered risk for major adverse CV events and all-cause mortality in patients with ACS on statin therapy, according to anticipated results of the ODYSSEY Outcomes trial presented as a late-breaking clinical trial at the American College of Cardiology Scientific Session. Valentin Fuster, MD, PhD, professor of medicine and cardiology at the Icahn School of Medicine at Mount Sinai, director of Mount Sinai Heart and physician in chief at the Mount Sinai Hospital, provided his take on the ODYSSEY Outcomes findings during a press conference. "I believe this study is going to change practice because of the hypothesis that has been fulfilled. The results were not trivial. There was a decrease in the primary endpoint by 15 percent. If LDL was more than 100 mg/dL, the decrease was 24 percent. It was interesting that the achieved LDL levels were very low. The message is that maybe what we consider a normal LDL level today is too high," he said.
- Valentin Fuster, MD, PhD, Professor, Medicine, Cardiology, Icahn School of Medicine at Mount Sinai, Director, Mount Sinai Heart, Physician in Chief, The Mount Sinai Hospital
Learn more
Additional coverage:
Reuters Health
MedPage Today
tctMD
AJMC